Skip to search formSkip to main contentSkip to account menu

MEDI 493

Known as: Monoclonal Antibody MEDI-493, MEDI-493, Monoclonal Antibody, MEDI-493 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

palivizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus.
We have identified a single tryptophan (Trp) residue responsible for loss of binding and biological activity upon ultraviolet (UV… 
Review
2000
Review
2000
Respiratory syncytial virus prevention: past and present strategies
Respiratory syncytial virus (RSV) is a common cause of respiratory illness in young children, almost all will have been infected… 
Highly Cited
1999
Highly Cited
1999
A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.
Two humanized monoclonal antibodies, MEDI-493 and RSHZ19, were developed independently as potential improvements over RSV-IGIV… 
Highly Cited
1998
Highly Cited
1998
Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
BACKGROUND Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants. MEDI-493… 
Highly Cited
1998
Highly Cited
1998
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.
Thirty-five children <2 years of age mechanically ventilated for respiratory syncytial virus (RSV) infection were randomized to… 
1998
1998
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group…
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493… 
Highly Cited
1998
Highly Cited
1998
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
Background.Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493… 
1998
1998
Phase I/II, Double-blind, Placebo-controlled, Multi-dose Escalation Trial of a Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody (MEDI-493) in Children Hospitalized with RSV • 906
MEDI-493, a humanized monoclonal antibody to the F-protein of RSV, is highly active against RSV. The objective of this study was… 
Highly Cited
1997
Highly Cited
1997
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.
Neutralizing polyclonal antibody to respiratory syncytial virus (RSV) has been shown to be an effective prophylactic agent when… 
1997
1997
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATION TRIAL OF A HUMANIZED RESPIRATORY SYNCYTIAL VIRUS (RSV) MONOCLONAL ANTIBODY (MEDI-493) IN HIGH RISK INFANTS. • 768
AIM: MEDI-493 is directed against the F protein of RSVand is broadly reactive against RSV in vitro. Serum levels of 25-30 ug/ml… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)